Broad Spectrum Anti-bacterial Agents
NuBiotics are a new class of novel antibiotics exhibiting broad spectrum bactericidal activity against both gram positive and gram negative bacteria. Not only are NuBiotics effective in killing a wide range of bacteria, they are also extremely effective in killing drug-resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and flesh-eating bacteria that pose an enormous threat to people throughout the world.
|
Chemical Structure of Nubiotics
|
These synthetic molecules are protonated/acidified oligonucleotides, nucleotides, and derivative molecules that exhibit chemical stability, acid pH resistance, and nuclease resistance allowing for multiple routes of delivery. With an optimum pH range between 1-4 and rapid effectiveness, NuBiotics are unlikely to function through inhibition of any nucleotide based process. Preliminary experiments indicate a mechanism involving disruption of the bacterial cell membrane which is further supported by their in vitro effectiveness against over 70 different bacterial strains including many antibiotic resistant strains. Lakewood Amedex scientists believe the NuBiotic mechanism of action will prove difficult for bacteria to circumvent, unlike the case with traditional antibiotics where antibiotic resistance is rapidly becoming a major problem for the healthcare industry. The compounds have been evaluated in a number of relevant animal models and proven effective in dramatically increasing survival. In both a rodent lung infections and burn wound model of Pseudomonas aeruginosa, NuBiotics have been shown to be an effective treatment with survival rates of greater than 95% versus 0% for controls.
|
Active Against the Most Problematic Bacterial Strains
|
The lead compound, designated Nu-3, is scheduled to enter human clinical trials in within the next 12 months and are being developed initially as a first line therapy for treatment of Pseudomonas aeruginosa, the most common gram negative bacterium found in nosocomial infections and MRSA, a gram positive bacterium, the “superbug” responsible for an increasing incidence of death in hospitals and the community. These first in-class drugs represent a new defense against the increasing number of antibiotic-resistant bacteria.
|
|
